1. No complete references are present in the provided text.
2. Macalino SJY, Billones JB, Organo VG, Carrillo M, Constancia O. In silico strategies in tuberculosis drug discovery. Molecules. 2020;25:665.
3. World Health Organization, Stop TB Initiative (World Health Organization). Treatment of Tuberculosis: Guidelines. World Health Organization, Geneva, Switzerland, 2010.
4. World Health Organization. Global Tuberculosis Report 2018. World Health Organization, Geneva, Switzerland, 2018.
5. Balganesh TS, Alzari PM, Cole ST. Rising standards for tuberculosis drug development. Trends in Pharmacological Sciences. 2008;29:576–581.
6. Ballell L, Field RA, Duncan K, Young RJ. New small-molecule synthetic antimycobacterials. Antimicrobial Agents and Chemotherapy. 2005;49:2153–2163.
7. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis. 2009;89:334–353.
8. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, Maddox C, Rasmussen L, Reynolds RC, Secrist JA III, Sosa MI, et al. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis. 2009;89:354–363.
9. Reynolds RC, Ananthan S, Faaleolea E, Hobrath JV, Kwong CD, Maddox C, Rasmussen L, Sosa MI, Thammasuvimol E, White EL, et al. High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis. 2012;92:72–83.
10. Petersen E, Maeurer M, Marais B, Migliori GB, Mwaba P, Ntoumi F, Vilaplana C, Kim K, Schito M, Zumla A. World TB day 2017: Advances, challenges and opportunities in the “end-TB” era. International Journal of Infectious Diseases. 2017;56:1–5.
11. Liu, N.; Cummings, J.E.; England, K.; Slayden, R.A.; Tonge, P.J. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. Journal of Antimicrobial Chemotherapy. 2011, 66, 564–573.
12. England, K.; Am Ende, C.; Lu, H.; Sullivan, T.J.; Marlenee, N.L.; Bowen, R.A.; Knudson, S.E.; Knudson, D.L.; Tonge, P.J.; Slayden, R.A. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. Journal of Antimicrobial Chemotherapy. 2009, 64, 1052–1061.
13. Xu, H.; Sullivan, T.J.; Sekiguchi, J.; Kirikae, T.; Ojima, I.; Stratton, C.F.; Mao, W.; Rock, F.L.; Alley, M.R.K.; Johnson, F.; et al. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry. 2008, 47, 4228–4236.
14. Tipparaju, S.K.; Mulhearn, D.C.; Klein, G.M.; Chen, Y.; Tapadar, S.; Bishop, M.H.; Yang, S.; Chen, J.; Ghassemi, M.; Santarsiero, B.D.; et al. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl–ACP reductase. ChemMedChem. 2008, 3, 1250–1257.
15. Lobanov, V. Using artificial neural networks to drive virtual screening of combinatorial libraries. Drug Discovery Today BIOSILICO. 2004, 2, 149–156.
16. Song, C.M.; Lim, S.J.; Tong, J.C. Recent advances in computer-aided drug design. Briefings in Bioinformatics. 2009, 10, 579–591.
17. Jorgensen, W.L. The many roles of computation in drug discovery. Science. 2004, 303, 1813–1818.
18. Xiang, M.; Cao, Y.; Fan, W.; Chen, L.; Mo, Y. Computer-aided drug design: Lead discovery and optimization. Combinatorial Chemistry & High Throughput Screening. 2012, 15, 328–337.
19. Zhang, S. Computer-aided drug discovery and development. Drug Design and Discovery. 2011, 716, 23–38.
20. Berman, H.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Research. 2000, 28, 235–242.
21. RSCB-PDB. A Structural View of Biology. 2021. Available online: https://www.rcsb.org/ (accessed on 8 November 2021).
22. Bruch, E.M.; Petrella, S.; Bellinzoni, M. Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead. Applied Sciences. 2020, 10, 4248.
23. Holton, S.J.; Weiss, M.S.; Tucker, P.A.; Wilmanns, M. Structure-based approaches to drug discovery against tuberculosis. Current Protein & Peptide Science. 2007, 8, 365–375.
24. Elkington, P.T.; Friedland, J.S. Permutations of time and place in tuberculosis. Lancet Infectious Diseases. 2015, 15, 1357–1360.
25. Hong, B.-Y.; Maulén, N.P.; Adami, A.J.; Granados, H.; Balcells, M.E.; Cervantes, J. Microbiome changes during tuberculosis and antituberculous therapy. Clinical Microbiology Reviews. 2016, 29, 915–926.
26. Getahun, H.; Matteelli, A.; Chaisson, R.E.; Raviglione, M. Latent Mycobacterium tuberculosis infection. New England Journal of Medicine. 2015, 372, 2127–2135.
27. Miller, L.G.; Asch, S.M.; Yu, E.I.; Knowles, L.; Gelberg, L.; Davidson, P. A population-based survey of tuberculosis symptoms: How atypical are atypical presentations? Clinical Infectious Diseases. 2000, 30, 293–299.
28. World Health Organization. Global Tuberculosis Report 2019. World Health Organization, Geneva, Switzerland. 2019.
29. Green, K.; Garneau-Tsodikova, S. Resistance in tuberculosis: What do we know and where can we go? Frontiers in Microbiology. 2013, 4, 208.
30. World Health Organization. Global Tuberculosis Report 2020. World Health Organization, Geneva, Switzerland. 2020, pp. 115–127.
31. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. World Health Organization, Geneva, Switzerland. 2015.
32. Horsburgh C.R. Jr., Barry C.E. III, Lange C. Treatment of tuberculosis. New England Journal of Medicine. 2015; 373: 2149–2160.
33. Mitchison D., Davies G. The chemotherapy of tuberculosis: Past, present and future [State of the art]. International Journal of Tuberculosis and Lung Disease. 2012; 16: 724–732.
34. Zhang Z., Yan J., Xu K., Ji Z., Li L. Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates. BMC Infectious Diseases. 2015; 15: 153.
35. Rich M., Jaramillo E. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Geneva, Switzerland. 2008.
36. Claiborne A.B., Guenther R.S., English R.A., Nicholson A. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. National Academies Press, Washington, DC, USA. 2013.
37. Wright A., Zignol M. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report: The World Health Organization/International Union against Tuberculosis and Lung Disease (WHO/Union) Global Project on Anti-Tuberculosis Drug Resistance Surveillance, 2002–2007. World Health Organization, Geneva, Switzerland. 2008.
38. Mahajan R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. International Journal of Applied and Basic Medical Research. 2013; 3: 1.
39. Vilchèze C., Jacobs W.R. Jr. The mechanism of isoniazid killing: Clarity through the scope of genetics. Annual Review of Microbiology. 2007; 61: 35–50.
40. Khan S.R., Morgan A.G.M., Michail K., Srivastava N., Whittal R.M., Aljuhani N., Siraki A.G. Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD+ adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites. Biochemical Pharmacology. 2016; 106: 46–55.
41. Preziosi P. Isoniazid: Metabolic aspects and toxicological correlates. Current Drug Metabolism. 2007; 8:839–851.
42. Rickman KA, Swancutt KL, Mezyk SP, Kiddle JJ. Isoniazid: Radical-induced oxidation and reduction chemistry. Bioorganic & Medicinal Chemistry Letters. 2013; 23:3096–3100.
43. Timmins GS, Deretic V. Mechanisms of action of isoniazid. Molecular Microbiology. 2006; 62:1220–1227.
44. Timmins GS, Master S, Rusnak F, Deretic V. Nitric oxide generated from isoniazid activation by KatG: Source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2004; 48:3006–3009.
45. Bulatovic VM, Wengenack NL, Uhl JR, Hall L, Roberts GD, Cockerill FR III, Rusnak F. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrobial Agents and Chemotherapy. 2002; 46:2765–2771.
46. Hu X, Li X, Huang L, Chan J, Chen Y, Deng H, Mi K. Quantitative proteomics reveals novel insights into isoniazid susceptibility in mycobacteria mediated by a universal stress protein. Journal of Proteome Research. 2015; 14:1445–1454.
47. Jena L, Waghmare P, Kashikar S, Kumar S, Harinath BC. Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug. International Journal of Mycobacteriology. 2014; 3:276–282.
48. Laurenzo D, Mousa SA. Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Tropica. 2011; 119:5–10.
49. Zhao LL, Sun Q, Liu HC, Wu XC, Xiao TY, Zhao XQ, Li GL, Jiang Y, Zeng CY, Wan KL. Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis isolates from China. Antimicrobial Agents and Chemotherapy. 2015; 59:2045–2050.
50. Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrobial Agents and Chemotherapy. 2008; 52:2027–2034.
51. He L, Wang X, Cui P, Jin J, Chen J, Zhang W, Zhang Y. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis. 2015; 95:149–154.
52. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: Classical and new drugs. Journal of Antimicrobial Chemotherapy. 2011; 66:1417–1430.
53. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: A review. International Journal of Tuberculosis and Lung Disease. 2003; 7:6–21.
54. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. Journal of Antimicrobial Chemotherapy. 2003; 52:790–795.
55. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Medicine. 1996; 2:662–667.
56. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tubercle and Lung Disease. 1998; 78:117–122.
57. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiology Spectrum. 2014; 2:MGM2-0023-2013.
58. Lemaitre N, Callebaut I, Frenois F, Jarlier V, Sougakoff W. Study of the structure–activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochemical Journal. 2001; 353:453–458.
59. Sheen P, Ferrer P, Gilman RH, López-Llano J, Fuentes P, Valencia E, Zimic MJ. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis. 2009; 89:109–113.
60. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nature Reviews Drug Discovery. 2013; 12:388–404.
61. Gillespie, S.H. Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrobial Agents and Chemotherapy. 2002; 46: 267–274.
62. Okamoto, S., Tamaru, A., Nakajima, C., Nishimura, K., Tanaka, Y., Tokuyama, S., Suzuki, Y., Ochi, K. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Molecular Microbiology. 2007; 63: 1096–1106.
63. Carette, X., Blondiaux, N., Willery, E., Hoos, S., Lecat-Guillet, N., Lens, Z., Wohlkönig, A., Wintjens, R., Soror, S.H., Frénois, F. Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands. Nucleic Acids Research. 2012; 40: 3018–3030.
64. DeBarber, A.E., Mdluli, K., Bosman, M., Bekker, L.-G., Barry, C.E. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the USA. 2000; 97: 9677–9682.
65. Vilchèze, C., Av-Gay, Y., Attarian, R., Liu, Z., Hazbón, M.H., Colangeli, R., Chen, B., Liu, W., Alland, D., Sacchettini, J.C., et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Molecular Microbiology. 2008; 69: 1316–1329.
66. Zhao, F., Wang, X.-D., Erber, L.N., Luo, M., Guo, A.-Z., Yang, S.-S., Gu, J., Turman, B.J., Gao, Y.-R., Li, D.-F., et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2014; 58: 1479–1487.
67. Mathys, V., Wintjens, R., Lefevre, P., Bertout, J., Singhal, A., Kiass, M., Kurepina, N., Wang, X.-M., Mathema, B., Baulard, A., et al. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2009; 53: 2100–2109.
68. Satta, G., Witney, A.A., Begum, N., Canseco, J.O., Boa, A.N., McHugh, T.D. Role of whole-genome sequencing in characterizing the mechanism of action of para-aminosalicylic acid and its resistance. Antimicrobial Agents and Chemotherapy. 2020; 64: e00675-20.
69. Fàbrega, A., Madurga, S., Giralt, E., Vila, J. Mechanism of action of and resistance to quinolones. Microbial Biotechnology. 2009; 2: 40–61.
70. Cheng, A.F., Yew, W.W., Chan, E.W.C., Chin, M.L., Hui, M.M.M., Chan, R.C.Y. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrobial Agents and Chemotherapy. 2004; 48: 596–601.
71. Gordeev, M.F.; Liu, J.; Wang, X.; Yuan, Z. Water-Soluble O-Carbonyl Phosphoramidate Prodrugs for Therapeutic Administration. U.S. Patent 9,382,276. 2016.
72. Wang, W.; Voss, K.M.; Liu, J.; Gordeev, M.F. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chemical Research in Toxicology. 2021, 34, 1348–1354.
73. Working Group on New TB Drugs, Stop TB Partnership. Clinical Pipeline. 2021. Available online: https://www.newtbdrugs.org/pipeline/clinical (accessed 7 November 2021).
74. Libardo, M.D.J.; Boshoff, H.I.; Barry, C.E. III. The present state of the tuberculosis drug development pipeline. Current Opinion in Pharmacology. 2018, 42, 81–94.
75. Bandodkar, B.; Shandil, R.K.; Bhat, J.; Balganesh, T.S. Two Decades of TB Drug Discovery Efforts—What Have We Learned? Applied Sciences. 2020, 10, 5704.
76. Palomino, J.C.; Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics. 2014, 3, 317–340.
77. Grzelak, E.M.; Choules, M.P.; Gao, W.; Cai, G.; Wan, B.; Wang, Y.; McAlpine, J.B.; Cheng, J.; Jin, Y.; Lee, H.; et al. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. Journal of Antibiotics. 2019, 72, 719–728.
78. Ahamad, S.; Rahman, S.; Khan, F.I.; Dwivedi, N.; Ali, S.; Kim, J.; Hassan, M.I. QSAR based therapeutic management of M. tuberculosis. Archives of Pharmacal Research. 2017, 40, 676–694.
79. Tiberi, S.; Vjecha, M.J.; Zumla, A.; Galvin, J.; Migliori, G.B.; Zumla, A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. International Journal of Infectious Diseases. 2021.
80. Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chemical Biology. 2007, 3, 323–324.
81. Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H.K.; Cechetto, J.; et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nature Medicine. 2013, 19, 1157–1160.
82. Kang, S.; Kim, R.Y.; Seo, M.J.; Lee, S.; Kim, Y.M.; Seo, M.; Seo, J.J.; Ko, Y.; Choi, I.; Jang, J.; et al. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent. Journal of Medicinal Chemistry. 2014, 57, 5293–5305.
83. Maeda, K. A new antibiotic, azomycin. Journal of Antibiotics. 1953, 6, 182.
84. Stover, C.K.; Warrener, P.; VanDevanter, D.R.; Sherman, D.R.; Arain, T.M.; Langhorne, M.H.; Anderson, S.W.; Towell, J.A.; Yuan, Y.; McMurray, D.N.; et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000, 405, 962–966.
85. Ginsberg, A.M.; Laurenzi, M.W.; Rouse, D.J.; Whitney, K.D.; Spigelman, M.K. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrobial Agents and Chemotherapy. 2009, 53, 3720–3725.
86. Sacksteder, K.A.; Protopopova, M.; Barry, C.E.; Andries, K.; Nacy, C.A. Discovery and development of SQ109: A new antitubercular drug with a novel mechanism of action. Future Microbiology. 2012, 7, 823–837.
87. Tahlan, K.; Wilson, R.; Kastrinsky, D.B.; Arora, K.; Nair, V.; Fischer, E.; Barnes, S.W.; Walker, J.R.; Alland, D.; Barry, C.E. III; et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2012, 56, 1797–1809.
88. Gordeev, M.F.; Yuan, Z.Y. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. Journal of Medicinal Chemistry. 2014, 57, 4487–4497.
89. Shoen, C.; DeStefano, M.; Hafkin, B.; Cynamon, M. In vitro and in vivo activities of contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2018, 62, e00493-18.
90. Chiliza, T.E.; Pillay, M.; Pillay, B. Identification of unique essential proteins from a Mycobacterium tuberculosis F15/Lam4/KZN phage secretome library. Pathogens and Disease. 2017, 75, ftx001.
91. Lamichhane, G. Novel targets in M. tuberculosis: Search for new drugs. Trends Mol. Med. 2011, 17, 25–33.
92. Bishi, L.Y.; Vedithi, S.C.; Blundell, T.L.; Mugumbate, G.C. Computational deorphaning of Mycobacterium tuberculosis targets. In: Drug Discovery and Development—New Advances. IntechOpen, London, UK, 2019.
93. Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S.H. Structure-based virtual screening for drug discovery: A problem-centric review. AAPS J. 2012, 14, 133–141.
94. Lavecchia, A.; di Giovanni, C. Virtual screening strategies in drug discovery: A critical review. Curr. Med. Chem. 2013, 20, 2839–2860.
95. Lavecchia, A.; Cerchia, C. In silico methods to address polypharmacology: Current status, applications and future perspectives. Drug Discov. Today 2016, 21, 288–298.
96. Moore, T.J.; Zhang, H.; Anderson, G.; Alexander, G.C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015–2016. JAMA Intern. Med. 2018, 178, 1451–1457.
97. Swinney, D.C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 2011, 10, 507–519.
98. Ferreira, L.G.; Dos Santos, R.N.; Oliva, G.; Andricopulo, A.D. Molecular docking and structure-based drug design strategies. Molecules 2015, 20, 13384–13421.
99. Anderson, A.C. The process of structure-based drug design. Chem. Biol. 2003, 10, 787–797.
100. Lionta, E.; Spyrou, G.; Vassilatis, D.K.; Cournia, Z. Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Curr. Top. Med. Chem. 2014, 14, 1923–1938.
101. Kalyaanamoorthy S, Chen Y-PP. Structure-based drug design to augment hit discovery. Drug Discovery Today. 2011;16:831–839.
102. Searls DB. Data integration: Challenges for drug discovery. Nature Reviews Drug Discovery. 2005;4:45–58.
103. Batool M, Choi S. Identification of druggable genome in Staphylococcus aureus multidrug resistant strain. Proceedings of the 2017 IEEE Life Sciences Conference (LSC), Sydney, Australia, 13–15 December 2017.
104. Blaney J. A very short history of structure-based design: How did we get here and where do we need to go? Journal of Computer-Aided Molecular Design. 2012;26:13–14.
105. Mandal S, Mandal SK. Rational drug design. European Journal of Pharmacology. 2009;625:90–100.
106. Wilson GL, Lill MA. Integrating structure-based and ligand-based approaches for computational drug design. Future Medicinal Chemistry. 2011;3:735–750.
107. Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: From molecular insights to therapeutic perspectives. Pharmacological Reviews. 2011;63:59–126.
108. Fang Y. Ligand–receptor interaction platforms and their applications for drug discovery. Expert Opinion on Drug Discovery. 2012;7:969–988.
109. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annual Review of Biophysics and Biomolecular Structure. 1998;27:249–284.
110. Clark DE. What has computer-aided molecular design ever done for drug discovery? Expert Opinion on Drug Discovery. 2006;1:103–110.
111. Rutenber, E.E.; Stroud, R.M. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: Assessing specificity and affinity. Structure. 1996; 4:1317–1324.
112. Wang, L.; Gu, Q.; Zheng, X.; Ye, J.; Liu, Z.; Li, J.; Hu, X.; Hagler, A.; Xu, J. Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations. Journal of Chemical Information and Modeling. 2013; 53:2409–2422.
113. Grover, S.; Apushkin, M.A.; Fishman, G.A. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. American Journal of Ophthalmology. 2006; 141:850–858.
114. Dadashpour, S.; Tuylu Kucukkilinc, T.; Unsal Tan, O.; Ozadali, K.; Irannejad, H.; Emami, S. Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and β-amyloid aggregation inhibitors. Archiv der Pharmazie. 2015; 348:179–187.
115. Miller, Z.; Kim, K.-S.; Lee, D.-M.; Kasam, V.; Baek, S.E.; Lee, K.H.; Zhang, Y.-Y.; Ao, L.; Carmony, K.; Lee, N.-R.; et al. Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. Journal of Medicinal Chemistry. 2015; 58:2036–2041.
116. Marrakchi, H.; Lanéelle, G.; Quémard, A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology. 2000; 146:289–296.
117. Ren, J.-X.; Li, L.-L.; Zheng, R.-L.; Xie, H.-Z.; Cao, Z.-X.; Feng, S.; Pan, Y.-L.; Chen, X.; Wei, Y.-Q.; Yang, S.-Y. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. Journal of Chemical Information and Modeling. 2011; 51:1364–1375.
118. Matsuno, K.; Masuda, Y.; Uehara, Y.; Sato, H.; Muroya, A.; Takahashi, O.; Yokotagawa, T.; Furuya, T.; Okawara, T.; Otsuka, M.; et al. Identification of a new series of STAT3 inhibitors by virtual screening. ACS Medicinal Chemistry Letters. 2010; 1:371–375.
119. Vallerand, A.H.; Sanoski, C.A. Davis’s Canadian Drug Guide for Nurses. FA Davis, Philadelphia, PA, USA. 2020.
120. Tripathi, K. Essentials of Medical Pharmacology. JP Medical Ltd., New Delhi, India. 2013.
121. Maia, E.H.B.; Assis, L.C.; de Oliveira, T.A.; da Silva, A.M.; Taranto, A.G. Structure-based virtual screening: From classical to artificial intelligence. Front. Chem. 2020, 8, 343.
122. Qaseem, A.; Kansagara, D.; Forciea, M.A.; Cooke, M.; Denberg, T.D. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2016, 165, 125–133.
123. Gambacorti-Passerini, C.; Antolini, L.; Mahon, F.-X.; Guilhot, F.; Deininger, M.; Fava, C.; Nagler, A.; della Casa, C.M.; Morra, E.; Abruzzese, E.; et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst. 2011, 103, 553–561.
124. Markowitz, M.; Nguyen, B.-Y.; Gotuzzo, E.; Mendo, F.; Ratanasuwan, W.; Kovacs, C.; Prada, G.; Morales-Ramirez, J.O.; Crumpacker, C.S.; Isaacs, R.D.; et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 2007, 46, 125–133.
125. Reymond, J.-L.; van Deursen, R.; Blum, L.C.; Ruddigkeit, L. Chemical space as a source for new drugs. MedChemComm 2010, 1, 30–38.
126. Ekins, S.; Freundlich, J.S.; Choi, I.; Sarker, M.; Talcott, C. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends Microbiol. 2011, 19, 65–74.
127. Macalino, S.J.Y.; Gosu, V.; Hong, S.; Choi, S. Role of computer-aided drug design in modern drug discovery. Arch. Pharm. Res. 2015, 38, 1686–1701.
128. Saxena, S.; Devi, P.B.; Soni, V.; Yogeeswari, P.; Sriram, D. Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening. J. Mol. Graph. Model. 2014, 47, 37–43.
129. Saxena, S.; Samala, G.; Sridevi, J.P.; Devi, P.B.; Yogeeswari, P.; Sriram, D. Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors. Eur. J. Med. Chem. 2015, 92, 401–414.
130. Reshma, R.S.; Saxena, S.; Bobesh, K.A.; Jeankumar, V.U.; Gunda, S.; Yogeeswari, P.; Sriram, D. Design and development of new class of Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors. Bioorg. Med. Chem. 2016, 24, 4499–4508.
131. Singh, S.; Khare, G.; Bahal, R.K.; Ghosh, P.C.; Tyagi, A.K. Identification of Mycobacterium tuberculosis BioA inhibitors by using structure-based virtual screening. Drug Design, Development and Therapy. 2018; 12:1065.
132. Taira, J.; Ito, T.; Nakatani, H.; Umei, T.; Baba, H.; Kawashima, S.; Maruoka, T.; Komatsu, H.; Sakamoto, H.; Aoki, S. In silico structure-based drug screening of novel antimycobacterial pharmacophores by DOCK-GOLD tandem screening. International Journal of Mycobacteriology. 2017; 6:142.
133. Billones, J.B.; Carrillo, M.C.O.; Organo, V.G.; Macalino, S.J.Y.; Sy, J.B.A.; Emnacen, I.A.; Clavio, N.A.B.; Concepcion, G.P. Toward antituberculosis drugs: In silico screening of synthetic compounds against Mycobacterium tuberculosis l,d-transpeptidase 2. Drug Design, Development and Therapy. 2016; 10:1147.
134. Korycka-Machala, M.; Nowosielski, M.; Kuron, A.; Rykowski, S.; Olejniczak, A.; Hoffmann, M.; Dziadek, J. Naphthalimides selectively inhibit the activity of bacterial, replicative DNA ligases and display bactericidal effects against tubercle bacilli. Molecules. 2017; 22:154.
135. Djaout, K.; Singh, V.; Boum, Y.; Katawera, V.; Becker, H.F.; Bush, N.G.; Hearnshaw, S.J.; Pritchard, J.E.; Bourbon, P.; Madrid, P.B.; et al. Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis. Scientific Reports. 2016; 6:27792.
136. Luciani, R.; Saxena, P.; Surade, S.; Santucci, M.; Venturelli, A.; Borsari, C.; Marverti, G.; Ponterini, G.; Ferrari, S.; Blundell, T.L.; et al. Virtual screening and X-ray crystallography identify non-substrate analog inhibitors of flavin-dependent thymidylate synthase. Journal of Medicinal Chemistry. 2016; 59:9269–9275.
137. Jeankumar, V.U.; Reshma, R.S.; Vats, R.; Janupally, R.; Saxena, S.; Yogeeswari, P.; Sriram, D. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. European Journal of Medicinal Chemistry. 2016; 122:216–231.
138. Sharma, K.; Tanwar, O.; Sharma, S.; Ali, S.; Alam, M.M.; Zaman, M.S.; Akhter, M. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents. Bioorganic Chemistry. 2018; 80:319–333.
139. Chiarelli, L.R.; Mori, M.; Barlocco, D.; Beretta, G.; Gelain, A.; Pini, E.; Porcino, M.; Mori, G.; Stelitano, G.; Costantino, L.; et al. Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents. European Journal of Medicinal Chemistry. 2018; 155:754–763.
140. Rohilla, A.; Khare, G.; Tyagi, A.K. Virtual screening, pharmacophore development and structure-based similarity search to identify inhibitors against IdeR, a transcription factor of Mycobacterium tuberculosis. Scientific Reports. 2017; 7:4653.
141. Dharra, R.; Talwar, S.; Singh, Y.; Gupta, R.; Cirillo, J.D.; Pandey, A.K.; Kulharia, M.; Mehta, P.K. Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein. PLoS ONE. 2017, 12, e0183060.
142. Gudzera, O.I.; Golub, A.G.; Bdzhola, V.G.; Volynets, G.P.; Lukashov, S.S.; Kovalenko, O.P.; Kriklivyi, I.A.; Yaremchuk, A.D.; Starosyla, S.A.; Yarmoluk, S.M.; et al. Discovery of potent anti-tuberculosis agents targeting leucyl-tRNA synthetase. Bioorganic & Medicinal Chemistry. 2016, 24, 1023–1031.
143. Gudzera, O.I.; Golub, A.G.; Bdzhola, V.G.; Volynets, G.P.; Kovalenko, O.P.; Boyarshin, K.S.; Yaremchuk, A.D.; Protopopov, M.V.; Yarmoluk, S.M.; Tukalo, M.A. Identification of Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) inhibitors among the derivatives of 5-phenylamino-2H-[1,2,4] triazin-3-one. Journal of Enzyme Inhibition and Medicinal Chemistry. 2016, 31(Suppl. 2), 201–207.
144. Petersen, G.O.; Saxena, S.; Renuka, J.; Soni, V.; Yogeeswari, P.; Santos, D.S.; Bizarro, C.V.; Sriram, D. Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase. Journal of Molecular Graphics and Modelling. 2015, 60, 124–131.
145. Lone, M.Y.; Athar, M.; Gupta, V.K.; Jha, P.C. Prioritization of natural compounds against Mycobacterium tuberculosis 3-dehydroquinate dehydratase: A combined in-silico and in-vitro study. Biochemical and Biophysical Research Communications. 2017, 491, 1105–1111.
146. Buryska, T.; Daniel, L.; Kunka, A.; Brezovsky, J.; Damborsky, J.; Prokop, Z. Discovery of novel haloalkane dehalogenase inhibitors. Applied and Environmental Microbiology. 2016, 82, 1958–1965.
147. Koes, D.R.; Camacho, C.J. Pharmer: Efficient and exact pharmacophore search. Journal of Chemical Information and Modeling. 2011, 51, 1307–1314.
148. Kim, S.; Thiessen, P.A.; Bolton, E.E.; Chen, J.; Fu, G.; Gindulyte, A.; Han, L.; He, J.; He, S.; Shoemaker, B.A.; et al. PubChem substance and compound databases. Nucleic Acids Research. 2016, 44, D1202–D1213.
149. Reddy, T.; Riley, R.; Wymore, F.; Montgomery, P.; DeCaprio, D.; Engels, R.; Gellesch, M.; Hubble, J.; Jen, D.; Jin, H.; et al. TB database: An integrated platform for tuberculosis research. Nucleic Acids Research. 2009, 37(Suppl. 1), D499–D508.
150. Galagan, J.E.; Sisk, P.; Stolte, C.; Weiner, B.; Koehrsen, M.; Wymore, F.; Reddy, T.B.K.; Zucker, J.D.; Engels, R.; Gellesch, M.; et al. TB database 2010: Overview and update. Tuberculosis. 2010, 90, 225–235.
151. Kapopoulou, A.; Lew, J.M.; Cole, S.T. The MycoBrowser portal: A comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis 2011, 91, 8–13.
152. Patni, K.; Agarwal, P.; Kumar, A.; Meena, L.S. Computational evaluation of anticipated PE_PGRS39 protein involvement in host–pathogen interplay and its integration into vaccine development. 3 Biotech 2021, 11, 204.
153. Rosenthal, A.; Gabrielian, A.; Engle, E.; Hurt, D.E.; Alexandru, S.; Crudu, V.; Sergueev, E.; Kirichenko, V.; Lapitskii, V.; Snezhko, E.; et al. The TB portals: An open-access, web-based platform for global drug-resistant-tuberculosis data sharing and analysis. Journal of Clinical Microbiology 2017, 55, 3267–3282.
154. Laskowski, R.A.; Jabłońska, J.; Pravda, L.; Vařeková, R.S.; Thornton, J.M. PDBsum: Structural summaries of PDB entries. Protein Science 2018, 27, 129–134.
155. Liu, R.; Li, X.; Lam, K.S. Combinatorial chemistry in drug discovery. Current Opinion in Chemical Biology 2017, 38, 117–126.
156. Shivanyuk, A.; Ryabukhin, S.V.; Tolmachev, A.; Bogolyubsky, A.V.; Mykytenko, D.M.; Chupryna, A.A.; Heilman, W.; Kostyuk, A.N. Enamine real database: Making chemical diversity real. Chemistry Today 2007, 25, 58–59.
157. Sterling, T.; Irwin, J.J. ZINC 15–ligand discovery for everyone. Journal of Chemical Information and Modeling 2015, 55, 2324–2337.
158. Ruddigkeit, L.; Van Deursen, R.; Blum, L.C.; Reymond, J.-L. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. Journal of Chemical Information and Modeling 2012, 52, 2864–2875.
159. Williams, A. ChemSpider: Integrating structure-based resources distributed across the Internet. Enhancing Learning with Online Resources, Social Networking, and Digital Libraries. ACS Symposium Series 2010, 1060, 23–29.
160. Gaulton, A.; Hersey, A.; Nowotka, M.; Bento, A.P.; Chambers, J.; Mendez, D.; Mutowo, P.; Atkinson, F.; Bellis, L.J.; Cibrián-Uhalte, E.; et al. The ChEMBL database in 2017. Nucleic Acids Research 2017, 45, D945–D954.
161. Voigt, J.H.; Bienfait, B.; Wang, S.; Nicklaus, M.C. Comparison of the NCI open database with seven large chemical structural databases. Journal of Chemical Information and Computer Sciences. 2001; 41: 702–712.
162. Schmidtke, P.; Le Guilloux, V.; Maupetit, J.; Tuffery, P. Fpocket: Online tools for protein ensemble pocket detection and tracking. Nucleic Acids Research. 2010; 38(Suppl. 2): W582–W589.
163. Le Guilloux, V.; Schmidtke, P.; Tuffery, P. Fpocket: An open source platform for ligand pocket detection. BMC Bioinformatics. 2009; 10: 168.
164. Hussein, H.A.; Borrel, A.; Geneix, C.; Petitjean, M.; Regad, L.; Camproux, A.-C. PockDrug-Server: A new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Research. 2015; 43: W436–W442.
165. Koes, D.R.; Camacho, C.J. PocketQuery: Protein–protein interaction inhibitor starting points from protein–protein interaction structure. Nucleic Acids Research. 2012; 40: W387–W392.
166. Brady, G.P.; Stouten, P.F. Fast prediction and visualization of protein binding pockets with PASS. Journal of Computer-Aided Molecular Design. 2000; 14: 383–401.
167. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009; 30: 2785–2791.
168. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein–ligand docking using GOLD. Proteins: Structure, Function, and Bioinformatics. 2003; 52: 609–623.
169. Schrödinger, G. Glide: A complete solution for ligand-receptor docking. 2021. Available online: https://www.schrodinger.com/products/glide (accessed 5 September 2021).
170. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. Journal of Molecular Biology. 1996; 261: 470–489.
171. BioSolveIT. SeeSAR: The Drug Design Dashboard. 2021. Available online: https://www.biosolveit.de/SeeSAR (accessed on 5 September 2021).
172. Tosco, P.; Balle, T. Open3DQSAR: A new open-source software aimed at high-throughput chemometric analysis of molecular interaction fields. Journal of Molecular Modeling. 2011, 17, 201–208.
173. Dong, J.; Yao, Z.-J.; Zhu, M.-F.; Wang, N.-N.; Lu, B.; Chen, A.F.; Lu, A.-P.; Miao, H.; Zeng, W.-B.; Cao, D.-S. ChemSAR: An online pipelining platform for molecular SAR modeling. Journal of Cheminformatics. 2017, 9, 27.
174. Schrödinger, Q. QikProp Rapid ADME Predictions of Drug Candidates. 2021. Available online: https://www.schrodinger.com/products/qikprop (accessed on 5 September 2021).
175. SimulationsPlus. ADMET Predictor: Flagship Machine Learning Platform for ADMET Modeling. 2021. Available online: https://www.simulations-plus.com/software/admetpredictor/ (accessed on 5 September 2021).
176. Potapov, V.; Cohen, M.; Inbar, Y.; Schreiber, G. Protein structure modelling and evaluation based on a 4-distance description of side-chain interactions. BMC Bioinformatics. 2010, 11, 374.
177. Laurie, A.T.; Jackson, R.M. Q-SiteFinder: An energy-based method for the prediction of protein–ligand binding sites. Bioinformatics. 2005, 21, 1908–1916.
178. Wunberg, T.; Hendrix, M.; Hillisch, A.; Lobell, M.; Meier, H.; Schmeck, C.; Wild, H.; Hinzen, B. Improving the hit-to-lead process: Data-driven assessment of drug-like and lead-like screening hits. Drug Discovery Today. 2006, 11, 175–180.
179. Smieško, M.; Vedani, A. VirtualToxLab: Exploring the toxic potential of rejuvenating substances found in traditional medicines. In: In Silico Methods for Predicting Drug Toxicity. Springer, Berlin/Heidelberg, 2016, pp. 121–137.
180. Krieger, E.; Joo, K.; Lee, J.; Lee, J.; Raman, S.; Thompson, J.; Tyka, M.; Baker, D.; Karplus, K. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins: Structure, Function, and Bioinformatics. 2009, 77, 114–122.
181. Bordoli, L.; Kiefer, F.; Arnold, K.; Benkert, P.; Battey, J.; Schwede, T. Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 2009, 4, 1–13.
182. Shi, Y.; Colombo, C.; Kuttiyatveetil, J.R.A.; Zalatar, N.; van Straaten, K.E.; Mohan, S.; Sanders, D.A.R.; Pinto, B.M. A second, druggable binding site in UDP-Galactopyranose mutase from Mycobacterium tuberculosis? ChemBioChem 2016, 17, 2264–2273.
183. Trott, O.; Vina, O.A. Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 2010, 31, 455–461.
184. Case, D.A.; Cheatham, T.E. III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K.M. Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R.J. The Amber biomolecular simulation programs. J. Comput. Chem. 2005, 26, 1668–1688.
185. Shoichet, B.K. Virtual screening of chemical libraries. Nature 2004, 432, 862–865.
186. Pedretti, A.; Mazzolari, A.; Gervasoni, S.; Vistoli, G. Rescoring and linearly combining: A highly effective consensus strategy for virtual screening campaigns. Int. J. Mol. Sci. 2019, 20, 2060.
187. Vidal, D.; Thormann, M.; Pons, M. A novel search engine for virtual screening of very large databases. J. Chem. Inf. Model. 2006, 46, 836–843.
188. Reddy, A.S.; Pati, S.P.; Kumar, P.P.; Pradeep, H.N.; Sastry, G.N. Virtual screening in drug discovery—a computational perspective. Curr. Protein Pept. Sci. 2007, 8, 329–351.
189. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 2000, 43, 4759–4767.
190. Willett, P.; Barnard, J.M.; Downs, G.M. Chemical similarity searching. J. Chem. Inf. Comput. Sci. 1998, 38, 983–996.
191. Bender, A.; Glen, R.C. A discussion of measures of enrichment in virtual screening: Comparing the information content of descriptors with increasing levels of sophistication. J. Chem. Inf. Model. 2005, 45, 1369–1375.
192. Batool, M.; Ahmad, B.; Choi, S. A structure-based drug discovery paradigm. Int. J. Mol. Sci. 2019, 20, 2783.
193. Ejalonibu, M.A.; Elrashedy, A.A.; Lawal, M.M.; Soliman, M.E.; Sosibo, S.C.; Kumalo, H.M.; Mhlongo, N.N. Dual targeting approach for Mycobacterium tuberculosis drug discovery: Insights from DFT calculations and molecular dynamics simulations. Struct. Chem. 2020, 31, 557–571.
194. Hartenfeller, M.; Schneider, G. De novo drug design. Chemoinformat. Comput. Chem. Biol. 2010, 672, 299–323.
195. Richardson, J.S.; Richardson, D.C. The de novo design of protein structures. Trends Biochem. Sci. 1989, 14, 304–309.
196. Lameijer, E.-W.; Tromp, R.A.; Spanjersberg, R.F.; Brussee, J.; IJzerman, A.P. Designing active template molecules by combining computational de novo design and human chemist’s expertise. J. Med. Chem. 2007, 50, 1925–1932.
197. Gillet, V.J. New directions in library design and analysis. Curr. Opin. Chem. Biol. 2008, 12, 372–378.
198. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 2005, 4, 649–663.
199. Keserű, G.M.; Makara, G.M. Hit discovery and hit-to-lead approaches. Drug Discov. Today 2006, 11, 741–748.
200. Tang, Y.; Zhu, W.; Chen, K.; Jiang, H. New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery. Drug Discov. Today Technol. 2006, 3, 307–313.
201. DeJesus, M.A., Gerrick, E.R., Xu, W., Park, S.W., Long, J.E., Boutte, C.C., Rubin, E.J., Schnappinger, D., Ehrt, S., Fortune, S.M., et al. Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. MBio. 2017; 8: e02133-16.
202. Jiménez-Luna, J., Cuzzolin, A., Bolcato, G., Sturlese, M., Moro, S. A deep-learning approach toward rational molecular docking protocol selection. Molecules. 2020; 25: 2487.
203. Abrahams, K.A., Besra, G.S. Mycobacterial drug discovery. RSC Med. Chem. 2020; 11: 1354–1365.
204. Billones, J.B., Carrillo, M.C.O., Organo, V.G., Sy, J.B.A., Clavio, N.A.B., Macalino, S.J.Y., Emnacen, I.A., Lee, A.P., Ko, P.K.L., Concepcion, G.P. In silico discovery and in vitro activity of inhibitors against Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (Mtb BioA). Drug Des. Dev. Ther. 2017; 11: 563.
205. Kumar, N., Srivastava, R., Prakash, A., Lynn, A.M. Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of Mycobacterium tuberculosis. J. Biomol. Struct. Dyn. 2020; 38: 3396–3410.
206. Tatum, N.J., Liebeschuetz, J.W., Cole, J.C., Frita, R., Herledan, A., Baulard, A.R., Willand, N., Pohl, E. New active leads for tuberculosis booster drugs by structure-based drug discovery. Org. Biomol. Chem. 2017; 15: 10245–10255.
207. Kingdon, A.D., Alderwick, L.J. Structure-based in silico approaches for drug discovery against Mycobacterium tuberculosis. Comput. Struct. Biotechnol. J. 2021; 19: 3708.
208. Rani, J., Silla, Y., Borah, K., Ramachandran, S., Bajpai, U. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis. J. Biomol. Struct. Dyn. 2020; 38: 2521–2532.
209. Zhang, G., Guo, S., Cui, H., Qi, J. Virtual screening of small molecular inhibitors against DprE1. Molecules. 2018; 23: 524.
210. Ali, M.T., Blicharska, N., Shilpi, J.A., Seidel, V. Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach. Sci. Rep. 2018; 8: 12238.
211. Ravichandran R, Ridzwan NFW, Mohamad SB. Ensemble-based high-throughput virtual screening of natural ligands using the Super Natural-II database against cell-wall protein dTDP-4-dehydrorhamnose reductase (RmlD) in Mycobacterium tuberculosis. J Biomol Struct Dyn. 2020, 1–10.
212. Scheich C, Szabadka Z, Vértesy B, Pütter V, Grolmusz V, Schade M. Discovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screen. PLoS ONE. 2011, 6, e28428.
213. Kaur G, Pandey B, Kumar A, Garewal N, Grover A, Kaur J. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae. J Biomol Struct Dyn. 2019, 37, 1254–1269.
214. Kumar N, Srivastava R, Prakash A, Lynn AM. Virtual screening and free energy estimation for identifying Mycobacterium tuberculosis flavoenzyme DprE1 inhibitors. J Mol Graph Model. 2021, 102, 107770.
215. Sundar S, Thangamani L, Manivel G, Kumar P, Piramanayagam S. Molecular docking, molecular dynamics and MM/PBSA studies of FDA approved drugs for protein kinase A of Mycobacterium tuberculosis; application insights of drug repurposing. Inform Med Unlocked. 2019, 16, 100210.
216. Kuldeep J, Sharma SK, Sharma T, Singh BN, Siddiqi MI. Targeting Mycobacterium tuberculosis enoyl-acyl carrier protein reductase using computational tools for identification of potential inhibitor and their biological activity. Mol Inform. 2021, 40, 2000211.
217. Sivaranjani P, Naik VU, Madhulitha NR, Kumar KS, Chiranjeevi P, Alex SP, Umamaheswari A. Design of novel antimycobacterial molecule targeting shikimate pathway of Mycobacterium tuberculosis. Indian J Pharm Sci. 2019, 81, 438–447.
218. Ballester PJ, Mangold M, Howard NI, Robinson RLM, Abell C, Blumberger J, Mitchell JBO. Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification. J R Soc Interface. 2012, 9, 3196–3207.
219. Chakraborty S, Rhee KY. Tuberculosis drug development: History and evolution of the mechanism-based paradigm. Cold Spring Harb Perspect Med. 2015, 5, a021147.
220. Mori G, Chiarelli LR, Esposito M, Makarov V, Bellinzoni M, Hartkoorn RC, Degiacomi G, Boldrin F, Ekins S, de Jesus Lopes Ribeiro AL, et al. Thiophenecarboxamide derivatives activated by EthA kill Mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG. Chem Biol. 2015, 22, 917–927.
221. Rabi, S.; Patel, A.H.G.; Burger, S.K.; Verstraelen, T.; Ayers, P.W. Exploring the substrate selectivity of human sEH and M. tuberculosis EHB using QM/MM. Structural Chemistry. 2017, 28, 1501–1511.
222. Ramalho, T.C.; Caetano, M.S.; Josa, D.; Luz, G.P.; Freitas, E.A.; da Cunha, E.F.F. Molecular modeling of Mycobacterium tuberculosis dUTpase: Docking and catalytic mechanism studies. Journal of Biomolecular Structure and Dynamics. 2011, 28, 907–917.
223. Oliveira, C.G.; Maia, P.S.; Souza, P.C.; Pavan, F.R.; Leite, C.Q.F.; Viana, R.B.; Batista, A.A.; Nascimento, O.R.; Deflon, V.M. Manganese(II) complexes with thiosemicarbazones as potential anti-Mycobacterium tuberculosis agents. Journal of Inorganic Biochemistry. 2014, 132, 21–29.
224. Chi, G.; Manos-Turvey, A.; O’Connor, P.D.; Johnston, J.M.; Evans, G.L.; Baker, E.N.; Payne, R.J.; Lott, J.S.; Bulloch, E.M.M. Implications of binding mode and active site flexibility for inhibitor potency against the salicylate synthase from Mycobacterium tuberculosis. Biochemistry. 2012, 51, 4868–4879.
225. Frisch, M.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; et al. Gaussian 09, Revision D.01. Gaussian Inc., Wallingford, CT, USA. 2009.
226. Stephens, P.J.; Devlin, F.J.; Chabalowski, C.F.; Frisch, M.J. Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. Journal of Physical Chemistry. 1994, 98, 11623–11627.
227. Becke, A.D. Density-functional thermochemistry. III. The role of exact exchange. Journal of Chemical Physics. 1993, 98, 5648–5652.
228. Indarto, A. Theoretical Modelling and Mechanistic Study of the Formation and Atmospheric Transformations of Polycyclic Aromatic Compounds and Carbonaceous Particles. Universal-Publishers, Gulf, CA, USA. 2010.
229. Hamada, I. van der Waals density functional made accurate. Physical Review B. 2014, 89, 121103.
230. Grimme, S. Accurate description of van der Waals complexes by density functional theory including empirical corrections. Journal of Computational Chemistry. 2004, 25, 1463–1473.
231. Cohen, A.J.; Mori-Sánchez, P.; Yang, W. Insights into current limitations of density functional theory. Science. 2008, 321, 792–794.
232. Villoutreix, B.O.; Eudes, R.; Miteva, M.A. Structure-based virtual ligand screening: Recent success stories. Combinatorial Chemistry & High Throughput Screening. 2009, 12, 1000–1016.
233. Talele, T.T.; Khedkar, S.A.; Rigby, A.C. Successful applications of computer aided drug discovery: Moving drugs from concept to the clinic. Current Topics in Medicinal Chemistry. 2010, 10, 127–141.
234. Clark, D.E. What has virtual screening ever done for drug discovery? Expert Opinion on Drug Discovery. 2008, 3, 841–851.
235. Scior, T.; Bender, A.; Tresadern, G.; Medina-Franco, J.L.; Martínez-Mayorga, K.; Langer, T.; Cuanalo-Contreras, K.; Agrafiotis, D.K. Recognizing pitfalls in virtual screening: A critical review. Journal of Chemical Information and Modeling. 2012, 52, 867–881.
236. Hassan Baig, M.; Ahmad, K.; Roy, S.; Mohammad Ashraf, J.; Adil, M.; Haris Siddiqui, M.; Khan, S.; Amjad Kamal, M.; Provazník, I.; Choi, I. Computer aided drug design: Success and limitations. Current Pharmaceutical Design. 2016, 22, 572–581.
237. Coupez, B.; Lewis, R. Docking and scoring—Theoretically easy, practically impossible? Current Medicinal Chemistry. 2006, 13, 2995–3003.
238. Fujita, T. Recent success stories leading to commercializable bioactive compounds with the aid of traditional QSAR procedures. Quantitative Structure-Activity Relationships. 1997, 16, 107–112.
239. Gao, Q.; Yang, L.; Zhu, Y. Pharmacophore based drug design approach as a practical process in drug discovery. Current Computer-Aided Drug Design. 2010, 6, 37–49.
240. Sardari, S.; Dezfulian, M. Cheminformatics in anti-infective agents discovery. Mini Reviews in Medicinal Chemistry. 2007, 7, 181–189.
241. Boström, J.; Norrby, P.-O.; Liljefors, T. Conformational energy penalties of protein-bound ligands. J. Comput.-Aided Mol. Des. 1998, 12, 383.
242. Perola, E.; Charifson, P.S. Conformational analysis of drug-like molecules bound to proteins: An extensive study of ligand reorganization upon binding. J. Med. Chem. 2004, 47, 2499–2510.
243. Verma, J.; Khedkar, V.M.; Coutinho, E.C. 3D-QSAR in drug design—a review. Curr. Top. Med. Chem. 2010, 10, 95–115.
244. Hu, Y.; Bajorath, J. Extending the activity cliff concept: Structural categorization of activity cliffs and systematic identification of different types of cliffs in the ChEMBL database. J. Chem. Inf. Model. 2012, 52, 1806–1811.
245. Hu, Y.; Stumpfe, D.; Bajorath, J. Advancing the activity cliff concept. F1000Research 2013, 2, 199.
246. Stumpfe, D.; de León, A.V.; Dimova, D.; Bajorath, J. Follow up: Advancing the activity cliff concept, part II. F1000Research 2014, 3, 75.
247. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: Molecular representations, data mining methods, new application areas, and performance evaluation. J. Chem. Inf. Model. 2010, 50, 205–216.
248. Jain, A.N.; Nicholls, A. Recommendations for evaluation of computational methods. J. Comput.-Aided Mol. Des. 2008, 22, 133–139.
249. Lindorff-Larsen, K.; Maragakis, P.; Piana, S.; Shaw, D.E. Picosecond to millisecond structural dynamics in human ubiquitin. J. Phys. Chem. B 2016, 120, 8313–8320.
250. Noé, F. Beating the millisecond barrier in molecular dynamics simulations. Biophys. J. 2015, 108, 228.
251. Shi J, Nobrega RP, Schwantes C, Kathuria SV, Bilsel O, Matthews CR, Lane TJ, Pande VS. Atomistic structural ensemble refinement reveals non-native structure stabilizes a sub-millisecond folding intermediate of CheY. Scientific Reports. 2017; 7:44116.
252. Park C-W, Seo SW, Kang N, Ko B, Choi BW, Park CM, Chang DK, Kim H, Kim H, Lee H, et al. Artificial intelligence in health care: Current applications and issues. Journal of Korean Medical Science. 2020; 35:e379.
253. Al-Attar S, Westra ER, Van Der Oost J, Brouns SJ. Clustered regularly interspaced short palindromic repeats (CRISPRs): The hallmark of an ingenious antiviral defense mechanism in prokaryotes. Biological Chemistry. 2011; 392:277–289.
